Table A1.

ORRs in Randomly Assigned Patients

ORR	ITT (n = 137)				MET Positive (n = 66)				MET Negative (n = 62)
	Placebo Plus Erlotinib (n = 68)		Onartuzumab Plus Erlotinib (n = 69)		Placebo Plus Erlotinib (n = 31)		Onartuzumab Plus Erlotinib (n =35)		Placebo Plus Erlotinib (n = 31)		Onartuzumab Plus Erlotinib (n = 31)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No. of patients experiencing OR	3	4.4*	4	5.8*	1	3.2	3	8.6	2	6.5	1	3.2
95% CI	1.2 to 11.7		2.0 to 13.9		0.2 to 16.1		2.4 to 21.5		1.2 to 20.0		0.2 to 16.1
Difference in ORR	1.4				5.3				−3.2
95% CI	−6.0 to 8.7				−5.8 to 16.5				−13.9 to 7.4
Stratified P	.7101				.3671				.6726

Abbreviations: ITT, intent to treat; OR, objective response; ORR, objective response rate.

^*Six of these patients had known EGFR mutation–positive tumors.